GALT vs PEPG
GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer. PEPG: PepGen is a biotechnology company developing novel oligonucleotide therapies that use proprietary peptide-based delivery technology to treat severe neuromuscular and neurological diseases.
Side-by-side fundamentals
| Metric | GALT | PEPG | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.38 | $1.78 | |
| Market cap as of 2026-07-31 | $230M | $118M | |
| ROE as of 2026-07-31 | -258.6% | -59.9% | PEPG higher |
| ROA as of 2026-07-31 | -164.7% | -49.6% | PEPG higher |
| Debt / equity as of 2026-07-31 | 11.09 | 0.00 | PEPG lower |
| Beta as of 2026-07-31 | 0.41 | 1.36 | |
| 1-year return as of 2026-07-27 close | +16.2% | +29.0% | PEPG higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.